Robeco Institutional Asset Management B.V. Lowers Stock Holdings in DexCom, Inc. $DXCM

Robeco Institutional Asset Management B.V. reduced its holdings in DexCom, Inc. (NASDAQ:DXCM) by 7.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 189,917 shares of the medical device company’s stock after selling 14,640 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in DexCom were worth $12,780,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in DXCM. Andra AP fonden purchased a new position in shares of DexCom during the 2nd quarter valued at approximately $26,000. Twin Peaks Wealth Advisors LLC acquired a new position in DexCom during the second quarter worth $26,000. SJS Investment Consulting Inc. lifted its holdings in DexCom by 4,800.0% during the third quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 384 shares in the last quarter. Financial Consulate Inc. acquired a new stake in shares of DexCom in the third quarter valued at about $29,000. Finally, Anderson Financial Strategies LLC acquired a new stake in shares of DexCom in the first quarter valued at about $37,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Activity at DexCom

In related news, Director Bridgette P. Heller sold 1,012 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total value of $58,766.84. Following the completion of the sale, the director owned 27,031 shares of the company’s stock, valued at approximately $1,569,690.17. This represents a 3.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Richard Alexander Collins sold 2,906 shares of the firm’s stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $59.05, for a total transaction of $171,599.30. Following the sale, the director owned 35,088 shares of the company’s stock, valued at approximately $2,071,946.40. The trade was a 7.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 7,866 shares of company stock valued at $448,177. 0.32% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts recently weighed in on DXCM shares. Piper Sandler set a $75.00 price target on shares of DexCom and gave the stock a “buy” rating in a research report on Friday, October 31st. Royal Bank Of Canada reduced their target price on DexCom from $100.00 to $85.00 and set an “outperform” rating for the company in a report on Friday, October 31st. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of DexCom in a research note on Monday, December 29th. Stifel Nicolaus assumed coverage on DexCom in a research report on Tuesday, October 21st. They set a “buy” rating and a $85.00 price target for the company. Finally, Morgan Stanley upgraded DexCom from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $63.00 to $75.00 in a report on Tuesday, December 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $86.61.

DexCom Price Performance

NASDAQ:DXCM opened at $68.43 on Friday. DexCom, Inc. has a one year low of $54.11 and a one year high of $93.25. The stock has a market cap of $26.69 billion, a PE ratio of 38.02, a P/E/G ratio of 1.26 and a beta of 1.48. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.38 and a current ratio of 1.56. The stock has a 50 day moving average price of $63.74 and a 200 day moving average price of $72.29.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The company had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.18 billion. During the same quarter in the previous year, the company posted $0.45 earnings per share. The firm’s revenue for the quarter was up 21.6% compared to the same quarter last year. Equities research analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.